Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil

被引:0
作者
Koper, Agnieszka [1 ,2 ]
Wilenski, Slawomir [3 ,4 ]
Sledzinska, Paulina [5 ]
Bebyn, Marek [5 ]
Koper, Krzysztof [2 ,6 ]
机构
[1] Nicolaus Copernicus Univ Torun, Dept Oncol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[2] Franciszek Lukaszczyk Oncol Ctr, Dept Oncol, PL-85796 Bydgoszcz, Poland
[3] Nicolaus Copernicus Univ Torun, Dept Pharmaceut Technol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[4] Hosp Pharm, F Lukaszczyk Oncol Ctr, Cent Cytostat Drug Dept, PL-85796 Bydgoszcz, Poland
[5] 10th Mil Res Hosp & Polyclin, PL-85681 Bydgoszcz, Poland
[6] Nicolaus Copernicus Univ Torun, Dept Clin Oncol & Nursing, Dept Oncol Surg, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
关键词
Chemotherapy; Colorectal cancer; Prognostic factors; Trifluridine/Tipiracil; TAS-102; MONOTHERAPY; PLUS BEVACIZUMAB; DOUBLE-BLIND; OPEN-LABEL; HYPERTENSION; SURVIVAL; THERAPY; REGORAFENIB; CETUXIMAB; TRIAL;
D O I
10.1007/s00432-023-04909-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The systemic treatment options for metastatic colorectal cancer (mCRC) are unsatisfactory, and the disease recurs despite the use of numerous medications and their combinations. Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC. Little is known about its real-world effectiveness and prognostic and predictive factors. Therefore, this study aimed to develop a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil. Methods We retrospectively evaluated the data from 163 patients who had received Trifluridine/Tipiracil as a third or fourth line of treatment for refractory mCRC. Results After starting Trifluridine/ Tipiracil, 21.5% of patients survived one year, and the median overall survival after Trifluridine/Tipiracil initiation was 251 days (SD: 17.855; 95%CI: 216-286). Median progression-free survival after Trifluridine/Tipiracil initiation was 56 days (SD: 4.826; 95%CI 47- 65). Moreover, the median overall survival from diagnosis was 1333 days (SD: 82.84; 95%CI: 1170-1495). In forward stepwise multivariate Cox regression analysis, initial radical treatment (HR = 0.552, 95% CI 0.372-0.819, p < 0.003), the number of cycles of first-line chemotherapy (HR = 0.978, 95% CI 0.961-0.995, p < 0.011), the number of cycles of second-line chemotherapy (HR = 0.955, 95% CI 0.931-0.98, p < 0.011), BRAF mutation (HR = 3.016, 95% CI = 1.207-7.537, p = 0.018), and hypertension (HR = 0.64, 95% CI = 0.44-0.931, p = 0.02) were all associated with survival after Trifluridine/Tipiracil initiation. Our model and model-based nomogram displayed an AUC of 0.623 for one-year survival estimation in the testing cohort. The C-index for the prediction nomogram was 0.632. Conclusion We have developed a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil based on five variables. Moreover, we reported a nomogram which could be used by oncologists in clinic visits on a daily basis.y
引用
收藏
页码:10867 / 10877
页数:11
相关论文
共 50 条
  • [21] Predicting Trifluridine/Tipiracil Treatment Outcomes in Refractory Metastatic Colorectal Cancer Patients: A Multicenter Exploratory Analysis
    Prejac, Juraj
    Omcen, Tomislav
    Radic, Jasna
    Vrdoljak, Eduard
    Frobe, Ana
    Plestina, Stjepko
    ONCOLOGY, 2024, 102 (03) : 217 - 227
  • [22] Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil
    Yoshiaki Fujimoto
    Ryota Nakanishi
    Mamoru Nukatsuka
    Kazuaki Matsuoka
    Koji Ando
    Takeshi Wakasa
    Hiroyuki Kitao
    Eiji Oki
    Yoshihiko Maehara
    Masaki Mori
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 1029 - 1038
  • [23] Predictive and Prognostic Role of Systemic Immune-Inflammation Index (SII) in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
    Malik, Mateusz
    Radecka, Barbara
    Gelej, Marek
    Jackowska, Aleksandra
    Filipczyk-Cisarz, Emilia
    Zurowska, Michalina
    Hetman, Katarzyna
    Foszczynska-Kloda, Malgorzata
    Kania-Zembaczynska, Beata
    Manka, Danuta
    Orlikowska, Marlena
    Bodnar, Lubomir
    BIOMEDICINES, 2024, 12 (09)
  • [24] Effectiveness, safety, and prognostic factors of trifluridine/tipiracil for the treatment of patients with metastatic colorectal cancer in routine clinical practice
    Martinez-Perez, Julia
    Espinosa-Montano, Marta
    Luque-Caro, Natalia
    Avino-Tarazona, Victoria
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (02) : 692 - +
  • [25] Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
    Tabernero, Josep
    Argiles, Guillem
    Sobrero, Alberto F.
    Borg, Christophe
    Ohtsu, Atsushi
    Mayer, Robert J.
    Vidot, Loick
    Vera, Shanti R. Moreno
    Van Cutsem, Eric
    ESMO OPEN, 2020, 5 (04)
  • [26] Metastatic Colorectal Cancer Management with trifluridine/tipiracil
    White, Teresa
    Larson, Heidi
    Minnella, Alexandra
    Hochster, Howard S.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (02) : E30 - E37
  • [27] Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil
    Cheung, W. Y.
    Kavan, P.
    Dolley, A.
    CURRENT ONCOLOGY, 2020, 27 (05) : E451 - E458
  • [28] Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
    Takahashi, T.
    Yamazaki, K.
    Oki, E.
    Shiozawa, M.
    Mitsugi, K.
    Makiyama, A.
    Nakamura, M.
    Ojima, H.
    Kagawa, Y.
    Matsuhashi, N.
    Okuda, H.
    Asayama, M.
    Yuasa, Y.
    Shimada, Y.
    Manaka, D.
    Watanabe, J.
    Oba, K.
    Yoshino, T.
    Yoshida, K.
    Maehara, Y.
    ESMO OPEN, 2021, 6 (02)
  • [29] Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan
    Kashiwa, Munenobu
    Matsushita, Ryo
    CLINICAL THERAPEUTICS, 2020, 42 (07) : 1376 - 1387
  • [30] Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS)
    Hamers, Patricia A. H.
    Vink, Geraldine R.
    Elferink, Marloes A. G.
    Stellato, Rebecca K.
    Dijksterhuis, Willemieke P. M.
    Punt, Cornelis J. A.
    Koopman, Miriam
    May, Anne M.
    CLINICAL COLORECTAL CANCER, 2022, 21 (02) : 154 - 166